(Updates with the latest stock move in the headline and the first paragraph.)
TriSalus Life Sciences (TLSI) shares were up 5.9% in Wednesday trading after the company said late Tuesday it received US Food and Drug Administration clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio.
TriNav Advance provides access to small, distal vessels via a compatible delivery microcatheter, the company said.
The company said it plans to initiate a limited market release of the TriNav Advance device over the coming weeks.
Price: $5.22, Change: $+0.29, Percent Change: +5.88%